Filing Flows › Industrials › OmniAb (OABI)
OmniAb (OABI) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 30, 2026 · OmniAb (OABI) Q3 2026 earnings results →
Q3 2026 Revenue up 78% year over year to $4.0M · 394¢ of every $1 of revenue lost · operating margin -409.9%
OmniAb made $4.0M in Q3 2026 (+78% Y/Y): Service revenue $2.8M, xPloration revenue $703K, Royalty revenue $355K. Operating margin -409.9%, net loss $15.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 30, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.0M in Q3 2026, up 78% year over year and down 70% from the previous quarter. Service revenue was the largest line at 71% of revenue. Service revenue added $1.6M year over year (up 139%), 94% of the total change. License and milestone revenue declined 84%.
Operating costs exceeded revenue by $16.4M, an operating margin of -409.9%. Total costs fell 0% while revenue rose 78%. The fastest-growing cost line was Other operating costs (+11%). The quarter ended with a net loss of $15.7M, wider than the previous quarter's $5.9M loss.
Operating cash flow was $10.6M. Non-cash charges added back $3.6M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items added $19.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 30, 2026 | $4.0M | +78% | -409.9% | −$15.7M | $10.6M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $13.4M | +244% | -49.5% | −$5.9M | $2.7M |
| Q1 2026 | 10-Q | May 7, 2026 | $14.4M | +247% | -54.3% | −$7.7M | −$4.9M |
| Q4 2025 | 10-K | Mar 4, 2026 | $8.4M | -22% | -188.2% | −$14.2M | −$5.7M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $2.2M | -46% | -810.2% | −$16.5M | −$9.8M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $3.9M | -49% | -416.2% | −$15.9M | −$5.1M |
| Q1 2025 | 10-Q | May 8, 2025 | $4.2M | +9% | -453.6% | −$18.2M | −$15.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About OmniAb
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence TM , which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
In its own words, from its 10-K, filed Mar 4, 2026.
OmniAb against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +78% against the peers' median +8%. Operating margin: -409.9% against the peers' median 12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| BIAF bioAffinity Technologies | Q3 2026 | $1.1M | -26% | -328.0% |
Source: OmniAb 10-Q on SEC EDGAR · CIK 1846253 · Services-Commercial Physical & Biological Research
Guidance and outlook
13F: who owns OABI and who is buying
More on OABI
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results